In Vitro Fertilization Market on Track to Surpass $40 Billion by 2032

Introduction

In 2022, the global In Vitro Fertilization (IVF) market was valued at US$ 19.5 billion and is estimated to register a CAGR of 7.8% between 2023 and 2032. IVF, a common form of Assisted Reproductive Technology (ART), involves combining egg and sperm in a laboratory to aid embryo development and implantation. The rising popularity of IVF and other assisted reproductive methods results in approximately half a million births annually.

Several key factors drive the growth of the global IVF market. Firstly, advanced genetic screening technologies enhance IVF success rates by preventing the transfer of genetic disorders during procedures. Expanded insurance coverage for IVF treatments also moderates costs and increases accessibility. Technological advancements, such as improved culture media and enhanced imaging systems, contribute to higher success rates. The development of non-invasive techniques and the integration of artificial intelligence (AI) for embryo selection are significant trends boosting IVF treatment efficiency and outcomes.

Fertility tourism further supports market growth. Cost-effective treatment options in countries like the Czech Republic attract international patients. In regions like North America, rising infertility rates due to lifestyle factors fuel demand for IVF solutions. The market is also experiencing significant advancements and strategic activities by leading companies. The increasing application of AI in IVF procedures enhances embryo selection and improves success rates. Companies like Oma Fertility, offering AI-informed fertility treatments, are setting new benchmarks for IVF success.

Additionally, advancements in imaging systems and sperm separation technologies drive the IVF market. Imaging systems are vital for better patient care during procedures, while sperm separation systems address growing issues of male infertility. The global IVF market is expanding in its instrumental and technological segments. High adoption rates in fertility and surgical centers dominate the market due to their comprehensive care and specialized expertise.

Key Takeaways

• In 2022, the global in vitro fertilization market was valued at $19.5 billion, with a projected CAGR of 7.8% from 2023 to 2032.
• IVF with ICSI represented 43% of the market due to its effectiveness, especially for male infertility, making it a preferred choice.
• The equipment segment is projected to hold 59% of the market share, driven by more IVF procedures and advanced technology.
• Fresh non-donor IVF cycles are expected to grow rapidly due to their high success rates, especially with unfrozen eggs.
• Fertility clinics led the market, accounting for over 79% of revenue, due to increased demand and accessibility.
• Delayed pregnancies and associated infertility risks have globally increased IVF adoption, linking infertility to delayed parenthood.
• The transfer of multiple embryos in IVF presents risks like premature birth and low birth weight, affecting market growth.
• Developing countries like India and Brazil offer affordable IVF treatments, creating significant opportunities in medical tourism.

In Vitro Fertilization Statistics

• IVF cycles saw an 11% increase from 69,000 in 2019 to 77,000 in 2022.
• Donor Insemination cycles remained stable at approximately 6,000 in 2022.
• Fresh embryo transfers reported a 31% pregnancy success rate in 2022.
• The highest IVF success rate was among patients aged 18-34, at 42%.
• The average age of first-time IVF patients exceeded 35 years in 2022.
• Donor Insemination patients had an average age of 33.6 years in 2022.
• In England and Wales, the average age for first births was 29.2 years in 2022.
• NHS-funded IVF cycles decreased to 27% in 2022 from 40% in 2012.
• NHS funding for IVF dropped by 17% in England and 16% in Wales from 2019 to 2022.
• Scotland experienced a 7% reduction in NHS-funded IVF cycles from 2019 to 2022.
• An IVF cycle typically spans 3 to 6 weeks.
• In 2021, IVF constituted over 99% of all assisted reproductive technology (ART) procedures.
• A total of 86,146 infants, or 2.3% of all U.S. births in 2021, were conceived via ART.
• About 9% of married U.S. women aged 15-49 experienced infertility.
• Similarly, approximately 9% of U.S. men aged 15-44 encountered infertility issues.
• Around 12.5% of U.S. women aged 15-49 have utilized infertility services in their lifetime.
• IVF accounts for 1.6% of all live births in the United States.
• In Europe, IVF contributes to 4.5% of all live births.
• Couples are deemed infertile if conception does not occur after 12 months of unprotected intercourse (or 6 months if the woman is 35 years or older).
• Laparoscopic surgery can enhance pregnancy rates from 4.7% to 30.7%.
• Endometriosis decreases IVF success rates, with more severe conditions yielding poorer outcomes.
• Poor semen quality is the sole cause of infertility in 20% of couples and contributes in another 20%.
• Medical or surgical treatments improve poor semen quality in about 50% of affected men.
• Natural cycle IVF has an 8% success rate per cycle.
• The cumulative success rate after three cycles of natural cycle IVF is 21%.
• Couples with male factor infertility can achieve success rates as high as 44% with natural cycle IVF.
• Live birth rate using minimal stimulation is about 49%, compared to 63% with the long GnRHa protocol.
• Oocytes are retrieved 34 to 36 hours after hCG administration.
• Blastocyst stage transfers increase live births per cycle with fewer embryos transferred.
• Embryo Transfer Guidelines (ASRM) allow up to 2 blastocysts for women under 37 years.
• Women aged 38 to 40 and 41 to 42 can have up to 3 blastocysts transferred.
• The incidence of severe Ovarian Hyperstimulation Syndrome (OHSS) ranges from 0.2% to 1% of all stimulation cycles.
• From 1980 to 2015, 19% of all twins and 25% of all triplets resulted from IVF.
• Women under 35 years have a 47.6% chance of live births via IVF, with 89.4% being singletons.
• Women aged 35-37 have a 30.7% chance of live births, with 90.3% being singletons.
• Women aged 38-40 have a 21.7% chance of live births, with 90.9% being singletons.
• Women aged 41-42 have a 10.4% chance of live births, with 93.6% being singletons.
• Women over 42 have a 3.1% chance of live births, with 94.9% being singletons.
• The average cost of an IVF cycle ranges from $12,000 to $17,000.
• Rapid weight gain of about 10 pounds can occur within 3 to 5 days in severe cases of OHSS.
• Progesterone is administered for 8 to 10 weeks post-embryo transfer to support the uterine lining and embryo growth.
• A pregnancy test is conducted about 12 to 14 days after embryo transfer to confirm pregnancy.
• A full IVF cycle typically lasts 2 to 3 weeks.
• Miscarriage rates are similar to natural conception—about 15% for those in their 20s and over 50% for those in their 40s.
• A small percentage of IVF cases result in ectopic pregnancies.
• IVF increases the likelihood of multiple pregnancies compared to natural conception.
• Higher success rates are observed in younger individuals; significantly lower after age 40.
• OHSS symptoms last up to a week; may extend if pregnancy occurs.
• Pregnancy confirmation post-IVF is done by a blood test at least 12 days after egg retrieval.

Emerging Trends

• Integration of Artificial Intelligence (AI): Artificial intelligence is transforming the landscape of In Vitro Fertilization (IVF) by enhancing the prediction of pregnancy outcomes. AI technologies are increasingly used to analyze embryo viability, which helps in selecting the most promising embryos for implantation. This advancement aims to boost the success rates of IVF treatments while simultaneously reducing the likelihood of miscarriages. By applying sophisticated algorithms that assess embryo development, AI is setting a new standard in reproductive technology, making the process more efficient and potentially more accessible to a broader range of individuals seeking fertility assistance.
• Advancements in Stem Cell Research: Stem cell technology is at the forefront of the next wave of fertility treatments. Researchers are investigating the potential of stem cells to regenerate damaged ovarian tissue and improve the quality of eggs available for fertilization. This groundbreaking approach could fundamentally alter treatment options for individuals with fertility issues, particularly those whose egg quality has diminished due to age or other health factors. By enhancing egg quality and ovarian function, stem cell innovations hold the promise of increasing the effectiveness of IVF treatments, thereby improving the chances of conception for many would-be parents.
• Enhanced Embryo Selection Techniques: New technologies, including time-lapse imaging and microfluidics, are revolutionizing the way embryos are selected during IVF procedures. These technologies allow for precise and continuous monitoring of embryos as they develop, enabling fertility specialists to select the best candidates for successful pregnancy based on more detailed and dynamic data. This enhanced selection process not only improves the accuracy of embryo selection but also optimizes the overall success rates of IVF cycles, making the journey to parenthood more promising for many couples.
• Cryopreservation Techniques: Cryopreservation, particularly through the method known as vitrification, is becoming more advanced and widely used in preserving reproductive cells. This technology freezes eggs, sperm, and embryos at ultra-low temperatures to halt all biological activity, preserving their viability for future use. The adoption of vitrification has made it possible for individuals and couples to plan their families more flexibly, allowing them to delay pregnancy for personal or medical reasons without compromising the quality of their genetic material.
• Non-Invasive Genetic Testing: The field of preimplantation genetic testing is evolving with the introduction of non-invasive methods to assess embryos for genetic abnormalities. These advancements are crucial as they minimize the risk to the embryo while providing essential genetic information. This shift is likely to increase the adoption of genetic testing in IVF, as it ensures the health of the embryo without compromising its potential for successful implantation. As these technologies mature, they are expected to become a standard step in the IVF process, providing prospective parents with peace of mind and significantly reducing the risk of genetic disorders.
• Automation and Robotics in IVF: The incorporation of robotics and automated systems in IVF clinics is streamlining various procedures, from sperm selection to embryo transfer. Automation reduces the scope for human error, enhances the consistency of the procedures, and can lead to more standardized and cost-effective treatments. By leveraging robotic precision and automation, fertility clinics can improve treatment outcomes, making IVF a more viable option for many people. This trend is part of a broader movement towards more efficient, accessible, and reliable medical treatments in the field of reproductive health.

Use Cases

• Treating Infertility: In vitro fertilization (IVF) is primarily employed to overcome various forms of infertility, a significant challenge for many couples. It addresses infertility issues stemming from several causes, such as age-related decline in fertility, polycystic ovarian syndrome (PCOS), and male factor infertility where sperm may have mobility or count issues. IVF stands out as the most advanced and effective form of assisted reproductive technology available today. By assisting in the fertilization process outside the body, IVF enhances the chances of conception for those who have struggled with infertility, providing hope and a potential solution to achieve pregnancy.
• Preventing Genetic Disorders: IVF is instrumental in preventing genetic disorders, offering a proactive approach to health before a child is born. Through genetic screening techniques like preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS), embryos can be examined for genetic abnormalities prior to implantation. This is particularly vital for couples with a known risk of passing on genetic conditions. By selecting embryos that do not carry inheritable diseases, parents can significantly increase the likelihood of a healthy offspring, making IVF a critical tool in managing genetic health.
• Fertility Preservation: Fertility preservation is a pivotal benefit of IVF, especially for individuals undergoing medical treatments that may compromise their fertility, such as chemotherapy or radiation therapy. IVF allows for the preservation of eggs or sperm before starting treatment, ensuring that patients have the option of having biological children in the future. This is particularly crucial for cancer patients who are in their reproductive years and wish to consider family planning post-treatment. The ability to safeguard reproductive material provides peace of mind and future possibilities for those facing such life-altering treatments.
• Enabling Family Building for Single and Same-Sex Couples: IVF extends the possibility of parenthood to single individuals and same-sex couples, thereby broadening family-building options across diverse demographics. It offers a pathway to biological parenthood where natural conception is not possible or preferable. For same-sex couples, IVF can involve a donor along with one partner providing the sperm or egg, thereby facilitating a biological connection with the child. This inclusive approach has significantly transformed the landscape of family building, aligning with evolving social structures and personal choices.
• Assisting with Advanced Maternal Age: With more individuals choosing to start families later in life, IVF serves as a crucial technology to assist with the natural decline in fertility that comes with advanced maternal age. Women over the age of 35 often face increased difficulties in conceiving naturally due to a decrease in the quantity and quality of eggs. IVF can mitigate these challenges by using techniques that optimize the chances of successful fertilization and implantation, thus providing older women a viable option to achieve pregnancy. This application of IVF aligns with changing societal norms around the timing of parenthood and career planning.

Conclusion

The global In Vitro Fertilization (IVF) market is poised for robust growth, fueled by advancements in fertility technology and increased accessibility to treatments. Europe emerges as a leading market, driven by heightened awareness and acceptance of IVF procedures. The adoption of innovative technologies, such as artificial intelligence for embryo selection and non-invasive genetic testing, continues to refine the efficacy and success rates of IVF treatments. These developments, alongside the expansion of genetic screening and fertility preservation techniques, offer new opportunities and promise enhanced outcomes for patients worldwide.

Discuss Your Needs With Our Analyst

Please share your requirements with more details so our analyst can check if they can solve your problem(s)

Request a Sample Download PDF